


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A compound of formula (1):



(1)

wherein:

R⁴ and R⁵ together are either -S-C(R⁶)=C(R⁷)- or -C(R⁷)=C(R⁶)-S-;

R⁶ and R⁷ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy and (1-4C)alkanoyl;

A is phenylene;

n is 0, 1 or 2;

R¹ is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*-(1-4C)alkylcarbamoyl, *N,N*-((1-4C)alkyl)₂carbamoyl, sulphonamoyl, *N*-(1-4C)alkylsulphonamoyl, *N,N*-((1-4C)alkyl)₂sulphonamoyl, -S(O)_b-(1-4C)alkyl (wherein b is 0, 1, or 2), -OS(O)₂-(1-4C)alkyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy and -NHSO₂-(1-4C)alkyl;

or, when n is 2, the two R¹ groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring optionally being substituted by one or two methyl groups;

one of R² and R³ is selected from R_Na, and the other is selected from R_Nb;

R_Na: (1-3C)alkyl, halo(1-3C)alkyl, dihalo(1-3)alkyl, trifluoromethyl, hydroxy(1-3C)alkyl, dihydroxy(2-3C)alkyl, cyano(1-3C)alkyl (optionally substituted on alkyl with hydroxy), methoxymethyl, ethoxymethyl, methoxyethyl, methoxymethoxymethyl, dimethoxyethyl, (hydroxy)(methoxy)ethyl, (amino)(hydroxy)(2-3C)alkyl, (aminocarbonyl)(hydroxy)(2-3C)alkyl, (methylaminocarbonyl)(hydroxy)(2-3C)alkyl, (dimethylaminocarbonyl)(hydroxy)(2-3C)alkyl,

(methylcarbonylamino)(hydroxy)(2-3C)alkyl, (methylS(O)_p)(hydroxy)(2-3C)alkyl (wherein p is 0, 1 or 2);

R_{Nb}: (1-4C)alkyl, halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](2-4C)alkyl, (hydroxy)[(1-4C)alkoxy](2-4C)alkyl, (amino)(hydroxy)(2-4C)alkyl, (aminocarbonyl)(hydroxy)(2-4C)alkyl, ((1-4C)alkylaminocarbonyl)(hydroxy)(2-4C)alkyl, (di(1-4C)alkylaminocarbonyl)(hydroxy)(2-4C)alkyl, ((1-4C)alkylcarbonylamino)(hydroxy)(2-4C)alkyl, ((1-4C)alkylS(O)_p)(hydroxy)(2-4C)alkyl (wherein p is 0, 1 or 2);

wherein any alkyl or alkoxy group within any group in R_{Na} and R_{Nb} may also optionally be substituted on an available carbon atom with a hydroxy group (provided that said carbon atom is not already substituted by a group linked by a heteroatom);
provided that if R² is (1-3C)alkyl or (1-4C)alkyl then R³ is not (1-4C)alkyl or (1-3C)alkyl;
or a pharmaceutically acceptable salt thereof.

2. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is selected from R_{Na}, and R³ is selected from R_{Nb}, wherein R_{Na} and R_{Nb} are as defined in Claim 1.

3. (cancelled)


4. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0.

5. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁶ and R⁷ are independently selected from hydrogen and halo.

6. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁶ and R⁷ are independently selected from hydrogen and chloro.

7. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein R_n is selected from (1-4C)alkyl, hydroxy(1-4C)alkyl, and (1-4C)alkoxy(1-4C)alkyl.

8. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula (1A):




wherein R^1 to R^7 , A and n are as defined in claim 1.

9. (cancelled)


10. (original) A pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

11-15. (cancelled)

16. (currently amended) A process for the preparation of a compound of formula (1) as claimed in claim 1, which process comprises:
reacting an acid of the formula (2):



or an acid chloride or ester ~~activated derivative~~ thereof; with an amine of formula (3):



and thereafter if necessary:

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt.

17. (previously presented) A compound of formula (1), or a pharmaceutically acceptable salt thereof, selected from:

2-chloro-*N*-{[(1*R*,2*R*)-1-[(methoxyacetyl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[[3-hydroxy-2-(hydroxymethyl)propanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

ethyl 3-[[[(1*R*,2*R*)-2-[[[(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl](methyl)amino]-3-oxopropanoate};

2-[[[(1*R*,2*R*)-2-[[[(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl](methyl)amino]-2-oxoethyl acetate};

2-chloro-*N*-{[(1*R*,2*R*)-1-[glycoloyl(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[glyceroyl(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[[[(2*S*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[[[(2*R*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[(3-hydroxypropanoyl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[glycoloyl(2-hydroxyethyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-((1*R*,2*R*)-1-(((2*S*)-2-hydroxypropanoyl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;

2-chloro-*N*-((1*R*,2*R*)-1-(((2*S*)-2-hydroxypropanoyl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*R*)-2,3-dihydroxypropanoyl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide

2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*S*)-2,3-dihydroxypropanoyl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

(2*S*)-*N*'-((1*R*,2*R*)-2-(((2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*^l-methylsuccinamide;

(2*S*)-*N*'-((1*R*,2*R*)-2-(((2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*^l-methylsuccinamide;

2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*S*)-2-hydroxybutanoyl)(methyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*S*)-2-hydroxy-3-methylbutanoyl)(methyl) amino)-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*S*)-4-(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)-2-hydroxy butanoyl)(methyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*R*)-2-hydroxy-3-(methylthio)propanoyl)(methyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

tert-butyl ((2*S*)-3-(((1*R*,2*R*)-2-(((2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1*H*-inden-1-yl)(methyl)amino)-2-hydroxy-3-oxopropyl) carbamate;

2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*S*)-3-cyano-2-hydroxypropanoyl)(methyl) amino)-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

N-((1*R*,2*R*)-1-[(*N*-acetylseryl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-2-chloro-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;

N-((1*R*,2*R*)-1-[(*N*-acetylseryl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-((1*R*,2*R*)-1-[methyl(L-seryl)amino]-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide hydrochloride;

2-chloro-*N*-((1*R*,2*R*)-1-[methyl(L-seryl)amino]-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide hydrochloride;

(2*S*)-*N*'-((1*R*,2*R*)-2-(((2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*^l-methylpentanediamide;

(2*S*)-*N*¹-((1*R*,2*R*)-2-(((2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹-methylpentanediamide;
2-chloro-*N*-((1*R*,2*R*)-1-(((2*S*)-2-hydroxy-3-methoxypropanoyl)(methyl) amino)-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*S*)-2-hydroxy-3-methoxypropanoyl)(methyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
2,3-dichloro-*N*-((1*R*,2*R*)-1-(((2*R*)-2-hydroxy-3-(methylsulfonyl)propanoyl)(methyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;
N-((1*R*,2*R*)-1-(((2*S*)-3-amino-2-hydroxypropanoyl)(methyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide hydrochloride;
(2*S*)-*N*¹-((1*R*,2*R*)-2-(((2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹,*N*⁴-dimethylsuccinamide;
(2*S*)-*N*¹-((1*R*,2*R*)-2-(((2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl) amino)-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹,*N*⁴,*N*⁴-trimethylsuccinamide;
2-chloro-*N*-((1*R*,2*R*)-1-[glyceroyl(2-hydroxyethyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;
2-chloro-*N*-((1*R*,2*R*)-1-(((2*R*)-2,3-dihydroxypropanoyl)(2-hydroxyethyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide; and
2-chloro-*N*-((1*R*,2*R*)-1-(((2*S*)-2,3-dihydroxypropanoyl)(2-hydroxyethyl)amino)-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide.

18. (original) A method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

19. (original) A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

20. (original) A method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.